Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Sep 25;20(11):7762–7776. doi: 10.1002/alz.14238

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Serum concentration profiles of MEDI1814 in patients with AD. (A) Single ascending dose. (B) Multiple ascending dose. Pharmacokinetic properties of MEDI1814 were consistent across single‐ and multiple‐dosing paradigms. Serum exposures were dose‐proportional, and concentrations declined in a biphasic manner with similar rates of elimination (effective mean serum half‐life ≈ 14–20 days). AD, Alzheimer's disease; IV, intravenous; MAD, multiple ascending dose; SAD, single ascending dose; SC, subcutaneous.